173 related articles for article (PubMed ID: 22963984)
1. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G; Moritz T;
Atherosclerosis; 2012 Oct; 224(2):526-31. PubMed ID: 22963984
[TBL] [Abstract][Full Text] [Related]
2. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G;
J Diabetes Complications; 2016; 30(4):693-9. PubMed ID: 26861948
[TBL] [Abstract][Full Text] [Related]
3. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Lachin J; Nathan DM; Virella G;
Diabetes; 2011 Feb; 60(2):582-9. PubMed ID: 20980456
[TBL] [Abstract][Full Text] [Related]
4. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.
Prasad A; Clopton P; Ayers C; Khera A; de Lemos JA; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1213-1221. PubMed ID: 28473443
[TBL] [Abstract][Full Text] [Related]
5. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.
Hunt KJ; Baker N; Cleary P; Backlund JY; Lyons T; Jenkins A; Virella G; Lopes-Virella MF;
Atherosclerosis; 2013 Dec; 231(2):315-22. PubMed ID: 24267245
[TBL] [Abstract][Full Text] [Related]
6. Immune Complexes and the Risk of CVD in Type 1 Diabetes.
Lopes-Virella MF; Bebu I; Hunt KJ; Virella G; Baker NL; Braffett B; Gao X; Lachin JM;
Diabetes; 2019 Sep; 68(9):1853-1860. PubMed ID: 31217176
[TBL] [Abstract][Full Text] [Related]
7. Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort.
Hunt KJ; Jaffa MA; Garrett SM; Luttrell DK; Lipson KE; Lopes-Virella MF; Luttrell LM; Jaffa AA;
Diabetes Care; 2018 Apr; 41(4):840-846. PubMed ID: 29382658
[TBL] [Abstract][Full Text] [Related]
8. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages.
Virella G; Wilson K; Elkes J; Hammad SM; Rajab HA; Li Y; Chassereau C; Huang Y; Lopes-Virella M
Clin Immunol; 2018 Feb; 187():1-9. PubMed ID: 28689783
[TBL] [Abstract][Full Text] [Related]
9. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.
Lopes-Virella MF; Carter RE; Baker NL; Lachin J; Virella G;
Nephrol Dial Transplant; 2012 Apr; 27(4):1416-23. PubMed ID: 21856760
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.
Lopes-Virella MF; Virella G
J Atheroscler Thromb; 2013; 20(10):743-54. PubMed ID: 23965492
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against aldehyde-modified collagen type IV are associated with risk of development of myocardial infarction.
Vallejo J; Dunér P; Fredrikson GN; Nilsson J; Bengtsson E
J Intern Med; 2017 Dec; 282(6):496-507. PubMed ID: 28944562
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
[TBL] [Abstract][Full Text] [Related]
13. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.
Lopes-Virella MF; Baker NL; Hunt KJ; Lyons TJ; Jenkins AJ; Virella G;
Diabetes Care; 2012 Jun; 35(6):1333-40. PubMed ID: 22511260
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to oxidized lipoproteins and their relationship to myocardial infarction.
Ryan M; Owens D; Kilbride B; Collins P; Johnson A; Tomkin GH
QJM; 1998 Jun; 91(6):411-5. PubMed ID: 9709459
[TBL] [Abstract][Full Text] [Related]
15. Modified LDL Immune Complexes and Cardiovascular Disease.
Lopes-Virella MF; Virella G
Curr Med Chem; 2019; 26(9):1680-1692. PubMed ID: 29792135
[TBL] [Abstract][Full Text] [Related]
16. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial.
Alele JD; Luttrell LM; Hollis BW; Luttrell DK; Hunt KJ;
Atherosclerosis; 2013 Jun; 228(2):502-7. PubMed ID: 23608249
[TBL] [Abstract][Full Text] [Related]
17. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.
Lopes-Virella MF; Baker NL; Hunt KJ; Lachin J; Nathan D; Virella G;
Atherosclerosis; 2011 Feb; 214(2):462-7. PubMed ID: 21156319
[TBL] [Abstract][Full Text] [Related]
18. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
Tsimikas S; Bergmark C; Beyer RW; Patel R; Pattison J; Miller E; Juliano J; Witztum JL
J Am Coll Cardiol; 2003 Feb; 41(3):360-70. PubMed ID: 12575961
[TBL] [Abstract][Full Text] [Related]
19. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction.
Mustafa A; Nityanand S; Berglund L; Lithell H; Lefvert AK
Circulation; 2000 Nov; 102(21):2576-81. PubMed ID: 11085959
[TBL] [Abstract][Full Text] [Related]
20. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.
Ravandi A; Boekholdt SM; Mallat Z; Talmud PJ; Kastelein JJ; Wareham NJ; Miller ER; Benessiano J; Tedgui A; Witztum JL; Khaw KT; Tsimikas S
J Lipid Res; 2011 Oct; 52(10):1829-36. PubMed ID: 21821825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
